<DOC>
	<DOCNO>NCT02202746</DOCNO>
	<brief_summary>The purpose study determine whether lucitanib safe effective treatment patient FGF aberrant metastatic breast cancer , well treatment patient biomarker negative ( FGF non-aberrant ) metastatic breast cancer .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy VEGFR-FGFR-PDGFR Inhibitor , Lucitanib , Given Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Lucitanib selective , orally available tyrosine kinase inhibitor target FGFR1-3 , VEGFR1-3 , PDGFRα β , activity relevant cell line animal model . The first human trial lucitanib demonstrate daily dose lucitanib provide durable clinical response patient FGFR1- 11q ( FGF3 , FGF4 , Cyclin D1 , FGF19 ) -amplified breast cancer . RECIST partial response ( PRs ) also observe patient know FGF abnormality . Based result , study design explore safety anti-tumor activity daily lucitanib breast cancer patient without alteration FGF pathway .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm metastatic breast cancer relapse refractory approve standard available treatment Prior treatment standard first line therapy metastatic setting Availability tumor tissue sufficient confirmatory test FGFR1 11q amplification status Demonstrated progression disease radiological clinical assessment ( Measurable disease accord RECIST Version 1.1 NOT require enrollment ) Estimated life expectancy &gt; 6 month Current recent treatment biologic anticancer therapy Ongoing AEs prior anticancer therapy Active central nervous system ( CNS ) metastases Clinically significant uncontrolled hypertension cardiac disease Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>MBC</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>HER2+</keyword>
	<keyword>Estrogen receptor positive</keyword>
	<keyword>ER+</keyword>
	<keyword>Triple negative</keyword>
	<keyword>FGFR1</keyword>
	<keyword>11q</keyword>
	<keyword>FGF aberrant</keyword>
	<keyword>Biomarker negative</keyword>
	<keyword>FGF non-aberrant</keyword>
</DOC>